HomeNBIX • NASDAQ
Neurocrine Biosciences, Inc.
$137.92
After Hours:
$137.92
(0.00%)0.00
Closed: Mar 28, 4:37:58 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$137.83
Day range
$135.97 - $138.72
Year range
$89.04 - $148.37
Market cap
13.72B USD
Avg Volume
930.85K
P/E ratio
55.79
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
515.20M25.05%
Operating expense
218.90M19.68%
Net income
147.70M65.96%
Net profit margin
28.6732.73%
Earnings per share
1.5424.19%
EBITDA
156.00M44.71%
Effective tax rate
25.48%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
1.03B4.28%
Total assets
3.25B37.27%
Total liabilities
1.02B54.24%
Total equity
2.23B
Shares outstanding
99.51M
Price to book
6.10
Return on assets
12.32%
Return on capital
15.13%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
147.70M65.96%
Cash from operations
123.50M-13.64%
Cash from investing
-201.80M-74.57%
Cash from financing
35.40M43.90%
Net change in cash
-42.60M-184.02%
Free cash flow
59.95M-50.80%
About
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Founded
1992
Employees
1,400
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu